Press Releases

 
Press Releases
  Date Title View
Mar 2, 2017
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at Cowen and Company's 37th Annual Health Care Conference to be held at the Marriott Copley Place in Boston, Massachusetts on Wednesd...
PDF
Feb 28, 2017
Fourth Quarter Revenue Increased 13% Versus Prior Year to $14.9 million Full Year Revenue Grew by 25% to $49.3 million Submitted FDA 510(k) Applications for ePlex Instrument and Respiratory Pathogen Panel Ended 2016 with More Than 55 Customer Agreements, Re...
PDF
Feb 9, 2017
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its fourth quarter earnings results after market close on Tuesday, February 28, 2017. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET o...
PDF
Jan 10, 2017
Q4 Revenue Increased 13% Versus Prior Year to $14.9 Million Full Year Revenue Grew 25% to $49.2 million ePlex® Global Commercialization Continued to Gain Momentum Ending 2016 with More Than 55 Customer Agreements, Representing Over 85 ePlex Instruments...
PDF
Dec 28, 2016
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2017 J.P. Morgan Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco, California, on Wednesday, January ...
PDF
Dec 22, 2016
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has submitted 510(k) applications to the FDA for its ePlex sample-to-answer instrument and Respiratory Pathogen Panel. ...
PDF
Nov 3, 2016
Third Quarter Revenue Increased 28% Versus Prior Year to $10.8 millionePlex® Gaining Momentum in Europe; Preparation for U.S. Launch UnderwayePlex Clinical Sample Testing Completed at Clinical Study Sites; Q4 FDA Submission on TrackCompleted $29 Million ATM Offering; Ended Q3 with Cash Balance of $54.2 milli...
PDF
Nov 1, 2016
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Form ...
PDF
Oct 20, 2016
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Thursday, November 3, 2016. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on...
PDF
Jul 28, 2016
Second Quarter Revenue Increased 64% Versus Prior Year to $12.5 millionePlex® Systems Installed at Twelve European CustomersePlex FDA Submission Expected in Fourth Quarter CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of ...
PDF
1
...
NextLast